Injectable Drug Delivery Market Is Estimated To Represent USD 931.1 Billion By 2024 | Grand View Research Inc.

Grand View Research, Inc. – Market Research And Consulting.

According to a report,“Injectable Drug Delivery Market Analysis, By Device Type (Self-injection Devices, Conventional Devices), By Formulation (Conventional Drug Delivery, Novel Drug Delivery), By Therapeutic Use (Autoimmune Disorders, Hormonal Disorders, Oncology), By End-user Application (Hospitals, Homecare Settings, Research Institutes, Clinical Laboratories), By Region (U.S, Canada, Germany, U.K, China, India, South Africa, Saudi Arabia, Brazil, Mexico) And Segment Forecasts From 2018 to 2024″,published by Grand View Research, Inc.The global injectable drug delivery market is expected to reach USD 931.1 billion by 2024. The increase in number of chronic diseases like diabetes and cancer has fueled the need for injectable drug delivery. Unlike other traditional forms of drug delivery, injectables allow maximum bioavailability of the pharmaceutical drug as it bypasses the first pass metabolism. With substantial growth in technological advancements, the devices being manufactured and marketed are built so as to cater to the specific needs of the patients.

 Key Takeaways from the report:

• North America is expected to lead the market for injectable drug delivery devices with the largest number of patients suffering from chronic diseases like diabetes and cancer along with autoimmune disorders. The reason why countries in North America are leading is due to the technological innovations and advanced research in the area that enable them to excel at designing new and improved drug delivery products.

• The Asia Pacific market is set to lead exceptionally well owing to the partnerships with other well established global players. This region has also witnessed enormous investments in research and development; thus, accelerating the growth of the injectables market in this region.

• The homecare settings has been the most profit garnering segment with a large cohort of patients suffering from chronic diseases and hence the resultant high utility of these devices at a primary level for better control and management of the disease.

• Some key market players include Pfizer, Inc., Schott AG, Becton, Dickinson and Company, Baxter International, Inc., and ELI Lilly & Co.

Injectable drug delivery market, by devices, 2013 – 2024 (USD Million)

With the advent of self-injection devices, injectable drugs can be self administered without the need of medical assistance. A large number of technology-oriented developments have taken place in the biologics market, which further increases the applicability of these injectable devices in the challenging disease areas. Self-injection devices have allowed patients suffering from diabetes to manage insulin levels with auto-injectors, pen-injectors, and needle-free injectors; thus, the homecare segment has been a large grosser in the end-user application.

The major restraints in this market are injuries and infections caused by needles, ambiguities related to regulatory reimbursements, sterility of the injectable drugs, and the preference of other drug delivery systems that possess less toxicity and are easy to administer. Despite these restraints, the market potential for injectable drug delivery products is tremendous with majority of the key players opting to injectables over other forms of delivery. The injectable drug delivery industry, based on product type is segmented into two sub-types namely self-injection devices and conventional injection devices. Further, on the basis of therapeutic use, the injectable drug delivery industry is segmented into autoimmune disorders, hormonal disorders, oncology, and others.

The injectable drug delivery industry by end-user application is categorized into hospitals, homecare settings, and others including research establishments, diagnostics, and clinical laboratories.

Regional Outlook

The major countries studied in this report are U.S, Canada, Germany, U.K, China, India, South Africa, Saudi Arabia, Brazil, and Mexico. The North America region is technologically better equipped to handle a large patient base, thus making them more competent in this market. With the prevalence of chronic disorders increasing in this region the need to develop newer and better drug delivery systems was witnessed here.

Countries like China and India dominate the Asia market with various options in their product rangewith specific alterations made to the products to suit the exact needs of the patients.With a large population in the Asian region, the need for drug delivery systems is large in this market thus fueling the necessity for IDD systems.

Ask Our Industry Expert for more details on report – www.grandviewresearch.com/inquiry/89/ibb

Therapeutic Use

According to therapeutic use, the industryis categorized into segments like auto-immune disorders, hormonal disorders, oncology, and others. The use of IDD devices finds major applications in the treatment of oncology and diabetes care. Chemotherapy for oncological diseases employs IDD devices to a large extent. On the other hand, diabetes care calls for administration of insulin, which is fulfilled with the aid of auto-injectors, pen-injectors, and needle-free injection devices.

Grand View Research has segmented the global injectable drug delivery market on the basis of device type, therapeutic use, formulation, end-user application, and region:

Injectable Drug Delivery by Type Outlook (Revenue, USD Million, 2013 – 2024)

• Devices

  • Self- injection devices

  • Conventional injection devices

• Formulation

  • Conventional Drug Delivery

  • Novel Drug Delivery

  • Others

Injectable Drug Delivery Therapeutic Use Outlook (Revenue, USD Million, 2013 – 2024)

• Autoimmune disorders

• Hormonal disorders

• Oncology

• Others

Injectable Drug Delivery Devices End-User Application Outlook (Revenue, USD Million, 2013 – 2024)

• Hospitals

• Homecare Settings

• Others

Injectable Drug Delivery Devices Regional Outlook (Revenue, USD Million, 2013 – 2024)

• North America

• Europe

• Asia Pacific

• Latin America

• MEA

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: www.grandviewresearch.com/industry-analysis/injectable-drug-delivery-devices-industry